Studies concerning the ability of an inhaled Pz-agonist to produce dose-related bronchodiatation are conflicting. In five asthmatic, five bronchitic, and five normal subjects, specific airway conductance ( G a w / v~) , flow-volume curves, and singlebreath nitrogen washout were recorded after noncumulative inhalation of 0.65 mg, 1.30 mg, 1.95 mg, and, in some subjects, 2.60 mg of metaproterenol sulfate. Bronchodilatation appeared to be dose-related and was best assessed by using G~W / V L ; in all but one subject with chronic bronchitis, there was a significant linear relationship between log dose and percent change in G~W / V L .
hen drugs (for instance, bronchodilators) act upon a receptor, there is an accepted functional relationship between the percentage of maximum response and the log dose. The curve is sigmoid and has an intermediate portion where the percentage of change is linearly related to the log dose.' This functional relationship is not only of theoretic interest but also of clinical significance, in that the administration and comparative assessment of bronchodilators are based on the implicit assumption that bronchodilatation is dose-dependent.
In man, in vitro studies have shown that bronchial smooth muscle perfused with a p-agonist relaxes in a log-dose fa~hion.~ With one exception: all in viuo studies in man have shown that there is indeed a linear correlation between the log dose of bronchodilator and the response of the airway^;"^ however, only one physiologic parameter has been recorded, cumulative doses were used,"" and when the drug was inhaled, the particle size was not reported.
significant log dose-responses in eight subjects, maximum midexpiratory flow being the most sensitive measurement of flow rate, followed in order by forced expiratory volume in one second, flow at 50 percent of forced vital capacity, peak expiratory flow rate, and flow at 75 percent of forced vital capacity. No log dose-response curve could be observed by using the single-breath nitrogenwashout technique. This demonstration of significant log dose-responses to inhaled metaproterenol is consistent with the response to drugs acting upon receptors and suggests that patients may benefit from increasing doses of bronchodilators.
The purpose of our investigation was to determine if, in man, noncumulative administration of an inhaled bronchodilator with known particle size would produce dose-related responses of the airways and, if so, which of the physiologic tests currently used for the detection of bronchodilatation would best document this relationship. Metaproterenol sulfate was chosen as the bronchodilator studied for the following reasons: (1) it is nebulized as a dry powder, a form which is more stable than the liquid aerosol;1° ( 2 ) bronchial changes are maximal within 30 to 60 minutes and persist at the same level for an additional 60 to 90 minutes," a property which allows the recording of more than a single measurement; and ( 3 ) metaproterenol has fewer cardiovascular side effects than isoproterenol.12
MATERIAL AND METHODS
Fifteen subjects were studied; five patients had asthma,= five had chronic bronchitis,l3 and five were healthy subjects. One of the subiects with chronic bronchitis produced 40 to 50 'From the Department of Medicine, pulmonary Section, "1 of pumlent sputum per day and might have had bronAbraham Lincoln School of Medicine, University of Illichiectasis. Two of the subjects with bronchial asthma were nois, Chicago.
in "free intervals," defined as a period of at least three Abstracted in part in Clinical Research (22:653A, 1974) . ''Presently Assistant Professor of Medicine, Pulmonary Divimonths in which no attacks were recorded. The other three sion, the Pritzker School of Medicine, University chiasthmatic subjects were having two to three attacks of c a~o .
asthma per week at the time of the study. Therapy with t~s i i s t a n t Professor of Medicine. bronchodilators was discontinued for at least 12 hours before Manusmipt received December 29; revision accepted Febthe administration of metaproterenol. N~ subject was treated ruary 16.
D~. pupa, B~ 93, 950 ~~~t 5gth street, with steroids. Table 1 summarizes the clinicd data and the  Chicago 60637 baseline respiratory function of the subjects with asthma and Metaproterenol sulfate (Alupenq) was administered at the beginning of a maximal inspiration. Each subject received on successive days four whiffs of a p l a c e w and one w W (0.65 mg), two whiffs ( 1.30 mg), and three whiffs ( 1.95 mg) of metaproterenol sulfate. To test the reproducibility of the responses, each of the 15 subjects had a repeat trial with a dose of 0.65 mg of metaproterenol sulfate. Five subjects (one asthmatic, three bronchitic, and one normal subject) had all three dose levels repeated. Four subjects (two asthmatic, one nonnal, and one bronchitic subject) also received four whiffs (2.60 mg), One of these subjects developed transient electrocardiographic ST-T changes, which precluded the use of larger doses.
Pulmonary function was recorded as follows: before and 60 minutes after the inhalation of a placebo or metaproterenol, specific airway conductance ( Gaw/VL), forced exing at functional residual capacity, the patient's volume signal was displayed in front of him. With the use of a computerized program,'5 the following measurements of flow were recorded: the expiratory flow-volume curve, the forced vital capacity ( FVC ), the forced expiratory volume in one second (FEVl), the FEVl/FVC ratio as a percentage, the mean forced expiratory flow during the middle half of the FVC ( FEF25-758, or maximum midexpiratory flow rate ) , the peak forced expiratory flow ( FEFmax), and the flow after 50 percent and 75 percent of the FVC had been exhaled (FEF50% and FEF758, respectively). The three recordings with the highest FEVl (absolute value) were used to calculate the mean and the best value for each measurement. As previously reported,l6 the best values did not necessarily belong to the same flow-volume curve.
The single-breath nitrogen-washout test was performed as described by Buist and Ross;l7-ls the closing volume ( C V )
piratory flow-volume curve, and single-breath nitrogen washwas expressed as a percentage of the vital capacity (CV/ out were recorded consecutively. The Gaw/VL was measured VC%), and the slope of the alveolar plateau was expressed in a constant-volume body plethysrnograph;l4 to assure pantas ANdL. The electrocardiogram was continuously monitored; blood pressure and an ECC were recorded every 15 a l u p e n t ( Boehringer Ingelheim Ltd., Elmsford, NY) deminutes throughout the study.
livers particles, 85 percent of which are less than 7p, with a mean mass diameter less than 4u l information ~rovided In order to keep the variability of the functional deter- analysis had a range of variation of less than 7 percent; ( 4 ) the changes in mean FEVl produced by placebo had to be less than 10% of the baseline value; and ( 5 ) the changes in FEVl produced by the same dose given at different times had to be statistically similar ( Student's t-test, P > 0.05 ) .
To confirm that a plateau in the response of the airways to metaproterenol existed, five subjects (one asthmatic, three bronchitic, and one normal subject) were given a dose of 1.30 mg of metaproterenol sulfate. For each measurement, in all subjects, the maximum changes were observed at 60 minutes and persisted up to 105 minutes.
The dose-response relationships were analyzed by the leastsquares method. 19 If not otherwise noted, the log doseresponse curves mentioned throughout this report are statistically significant ( P < 0.05). The study was approved by the Committee on Human Investigation, and informed consent was obtained from each subject.
In all subjects but one who had bronchitis (patient 5, Table l ) , there was a linear relationship between the log dose and the percent change (or change in log units) of GawlV~. I I I I Detailed information on each subject can be obtained upon request from the authors.
Measurements of flow rate were less sensitive in demonstrating a log dose-response relationship. In eight subjects, log dose-response curves were obtained by using the mean value of various flow measurements. Seven were obtained by use of the FEF25-7516, four by the FEVI, four by the F E F m , two by the FEFmax, and one by the FEF75% and the FVC. In the same subjects and recording the same flow measurement, log doseresponse curves were also obtained by using the best values instead of the mean values. In two subjects (patients 3 and 7, Table l ) , additional log doseresponse curves were recorded by using the best values for FEF25-75% and in patient 3 also by using the best values for FEFmax.
No log dose-response curves could be obtained by using either CV/VC% or ANdL (Fig 1 to 3 ) .
In all normal subjects, log dose-response curves were obtained by using G a w l V~ and, in one subject, by using the F E F m and the FEF25-75% as well. Similarly, the asthmatic subjects with FEV,/FVC ratio greater than 75 percent and minimal, if any, decrease in basal flow rate measurements (patients 8 and 10, Table 1 ) showed log dose-response relationships using GawlV~. In only one subject (patient 10, Table 1 ) was a log dose-response curve demonstrated by measuring the FEF25-75% as well (Fig  1 ) . The asthmatic subjects with FEVI/FVC ratio smaller than 75 percent had log dose-responses demonstrated by G a w l V~ and at least three measurements of flow rate (Fig 2) . The log dose-response curves obtained in the subjects with bronchitis were rather heterogeneous. In one bronchitic subject with possible bronchiectasis (patient 5, Table l ) , there was no change at all in GawlV~, but log dose-response curves could be obtained by using the FEF25-75%; one bronchitic subject with mild obstruction (patient 1, Table 1 ) had a single log dose-response demonstrated by using G a w l V~; and the three remaining bronchitic subjects had log doseresponse curves demonstrated by G a w l V~ and at least one measurement of flow rate (Fig 2) . An unusual pattern of dose-related airway responses was noted in two subjects; in one normal subject (Fig 3 ) and in a subject with chronic bronchitis (patient 3, Table I ) , 0.65 mg of metaproterenol sulfate increased G a w l V~ but decreased the measurements of flow rate. This pattern was reproducible in both subjects. At higher doses, G a w l V~ continued to increase in a log-dose fashion; however, instead of further decreasing, the flows increased either to the baseline level (in the normal subject) or above it (in patient 3 with bronchitis).
Blood pressure and heart rate did not change significantly after administration of metaproterenol. With the exception of patient 4 (Table l ) , who, after inhalation of 2.60 mg of metaproterenol sulfate, had inversion of his precordial T waves, no subject showed an electrocardiographic abnormality.
This study shows that statistically significant noncumulative log dose-response curves to inhaled metaproterenol can be recorded in normal, asthmatic, and bronchitic subjects; however, not all of the physiologic parameters were equally valuable in demonstrating log dose-response curves. With the exception of one bronchitic subject (patient 5, Table  1 ) with possible large-airway involvement ( bronchiectasis ) , measurement of Gaw/ VL revealed log dose-response curves in all subjects, whereas mea- log dose-response curves in only eight subjects. The CV/VC% and A N~/ L could never define statistically significant log dose-response curves. The sensitivity of Gaw/VL for the determination of airway responses to single inhaled doses of bronchodilators is well e s t a b l i~h e d .~~.~~ The reason for this special sensitivity of G a w l V~ as compared to flow responses is not readily apparent. The following three explanations can be offered: ( 1 ) the preferential deposition of the inhaled aerosol in large airw a y~,~~ or ( 2 ) the avoidance of dynamic compression of airways during the determination of G~w / V L ,~~ or ( 3 ) both. In this study, there was no ceiling of response on the log dose-response curves obtained by using GawlV~. This finding is in agreement with the reports of Warrel et a15 and Paterson6 and underscores the usefulness of the determination of G a w l V~ in the evaluation of airway responses to administration of bronchodilators.
In two asthmatic patients in free intervals (patients 8 and 10, Table l ) (Fig l ) , G a w l V~ was normal, and the flow rate measurements were only minimally abnormal. The fact that the dose-related G a w l V~ responses of these two subjects to metaproterenol therapy were comparable to those of normal subjects (eg, the subject of Fig 3 ) suggests that padrenergic blockade was not present. If p-adrenergic blockade had been present, one would have expected the log dose-response curve to shift to the right. Our conclusion is also supported by the findings of Sob01 et al,24 who reported that in controls and asthmatic subjects with a normal GawlV~, single doses of isoproterenol produced a comparable increase in the Gaw/ VL.
It is interesting to note that log dose-response curves could be obtained by plotting log dose either against percent changes of the G a w l V~ or, as reported by Warrel et a15 and Pater~on,~ against log changes in the GawlV~. The use of log G a w l V~ normalizes the skewed distribution of G~w / V L .~~ Because we could obtain log dose-response curves by using either plot, the preference for a A log Gaw1V~-log dose diagram remains to be demonstrated by a study in a larger population with a wider range of GawlV~.
In eight subjects, there was a linear relationship between log dose and changes in various flow measurements. Nineteen log dose-response curves could be obtained in these subjects by using FEF25-75% (seven curves), using FEVl and F E F m (four curves each), using FEFrnax (two curves), and using FEF25% and FVC (one curve each). The latter three measurements defined dose-response curves only in those subjects in whom these curves were also detected by FEF2.5-75%, FEVl, or ing response to single doses of bronchodilators. As most of the log dose-response curves were obtained by using G a w l V~, FEVI, FEF5016, and FEF25-75%, but not by using FEF75%, it is a likely assumption that in this study the large and mediumsized airways played a much more importkt role in the dose-related response than did the small airways.
The incidence of log dose-flow responses was different in normal, asthmatic, and bronchitic subjects; and to some extent, these difFerences appeared to be related to the presence of bronchial obstruction, as d e h e d by a low FEVlIFVC. Indeed, three of the eight subjects with a value for FEVlIFVC greater than 75 percent had only four log doseresponse curves by using measurements of flow rate. In contrast, in the subjects with bronchial obstruction, the dose-related flow response was more consistent; five of the seven subjects with a value for FEVIIFVC less than 75 percent had 15 log doseresponse curves by using various flow parameters. These log dose-responses did not reach a plateau, a finding in agreement with two previous reports,'~~ but in sharp contrast to ~t h e r s .~.~ The recording of more than one forced expiratory flow parameter can detect the progressive increase in bronchodilation which may not be visible with one particular flow parameter. Consider patient 10 in Table 1 (Fig 1 ) ; FVC and FEFmax remained unchanged, FEVl and FEF75% leveled off after one whiff of metaproterenol sulfate, but the FEF25-75% showed a continuously increasing bronchodilation within the dose range used. For this reason, it is d8cult to compare our results with those obtained by others, because, among other differences, in all previous investigations only one flow measurement was recorded. Because log dose response curves could rarely be documented by means of all flow parameters, it is not surprising that Williams and KaneS did not detect any dose-related responses. These authors used only one flow measurement and also selected the one with the lowest yield in log dose-responses ( FEFmax ) .
In the assessment of dose-related flow responses, the best values appear to give a somewhat higher yield than mean values, since 22 log dose-response curves were generated by using best flow values and 19 by mean flow values; however, since variability of measurement is not taken into consideration when best values are used, we believe that mean values should be preferred for the assessment of the doserelated responses of the forced expiratory flows to inhaled bronchodilator therapy.
Inhalation of increasingly larger doses of metaproterenol produced changes in the CV/VC% and ANdL unrelated to log dose and also lacking any consistent direction of variation, ie, progressive increase or decrease, with the dose of metaproterenol (Fig 1 to 3) . This observation indicates that the CV/VC% and the AN2/L should not be used for the determination of dose-related airway responses to administration of bronchodilators.
Bronchodilator-induced collapse of the large airways has been previously documented by Bouhuys and van de W o e~t i j n e .~~ In our study, this phenomenon was suggested by the discordant flowconductance response (decreased flows, increased conductance) to 0.65 mg of metaproterenol sulfate occurring in two subjects (patient 3, Table 1 ; and the subject of Fig 3 ) . In this context, two aspects previously unreported are of interest. First, a patient with obstructive bronchitis (patient 3, Table 1 ) was able to display this pattern of response, suggesting that the large airways, even in the (probable) presence of ifitrates of the bronchial walls, can collapse. Second, in both subjects the discrepant flowconductance response disappeared when the dose of bronchodilator was increased; the exact mechanism of this phenomenon remains unknown.
In spite of our efforts to control as many variables as possible, the airway responses to an inhaled bronchodilator are still dependent on many factors which are most m c u l t , if not impossible, to determine, eg, deposition of the aerosol particles along the tracheobronchial tree, inflammatory infiltrates of the bronchial walls, receptor binding of the bronchoactive substance, etc. Moreover, the reproducibility of the airway responses to bronchodilators should be determined in large populations of normal, asthmatic, and bronchitic subjects before the log dose-response curves to an inhaled bronchodilator can be accepted as a standardized pharmacologic method. Nevertheless, we believe that the present study has demonstrated the feasibility of determining log doseresponses to an inhaled bronchodilator, has defined the tests most likely to reveal dose-related responses, and has c o h e d and extended the prevalent clinical impression, as well as the results of most multiple-dose rep~rts,".~ that increasingly larger doses of bronchodilator produce larger responses.
The clinical implication of our findings is obvious. In patients with obstructive airway disease, an increase in the dose of a bronchodilator is followed by increased bronchodilation and, thus, further relief of airway obstruction; however, this should not lead to the indiscriminate use of high doses of p-adrenergic agonists, especially when their potentially dangerous side effects cannot be promptly identified.
